思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 近日 ， 美敦力 Medtronic 宣布 任命 Joon Lee 博士为公司董事会新任独立董事 ，任命自2025年6月18日起 生效。 # 关于 Joon Lee 博士 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 Lee博士 在医疗政策、医院运营和医患关系创新方面有显著贡献，曾参与美国医疗协会和其他行业组织的顾 问工作。目前担任 美国埃默里医疗系统（Emory Healthcare）的首席执行官（CEO） ，这是乔治亚州最大 的学术医疗系统，涵盖11家医院、250个医疗点和超过2,800名医生。以下是Joon Lee博士的重要职业履历： 现任职位 埃默里医疗系统CEO （2021年至今）：领导该系统在医疗服务、研究和教育领域的全面运营，推动其在心血 管、神经科学、癌症治疗和数字化医疗领域的卓越表现。埃默里医疗系统 年收入约56亿美元 ，与美敦力的医 疗技术产品线（如 心脏起搏器、神经调控设备 ）高度相关。负责 整合医疗技术与临床实践，推进远程监护、 ...

7201.JP 250.00 JPY 9 June 2025 Japan Autos & Auto Parts Nissan Motor Co Ltd Rating Underperform Price Target Tomohiro Kashimoto +81 3 6777 6975 tomohiro.kashimoto@bernsteinsg.com Nissan: Q1 profits might look better than guidance, but the path to a turnaround is going to be a tough climb What has changed and is unchanged. While we have lowered our forecasts by incorporating company feedback following the FY3/25 results and the impact of US tariffs, we have maintained our price target at ¥250 after making ad ...

【文/观察者网 刘程辉】 为应对中国车企的强势竞争，欧洲老牌车企开始有样学样了。 "比亚迪与中国同行如何重塑欧洲小型电动车市场"，香港英文媒体《南华早报》6月9日以此为题报道指 出，随着比亚迪等中国电动汽车制造商发力欧洲小型车市场，大众、雷诺等欧洲老牌车企也准备推出一 系列低成本小型车以加强竞争力。业内人士表示，欧洲一直难以推出具有竞争力的小型车，采用在中国 已非常流行的磷酸铁锂电池技术，将有助于车企降低成本。 报道注意到，去年超越特斯拉成为全球最大电动车制造商的中国车企比亚迪，上个月在欧洲推出了紧凑 型掀背车"海鸥"（Dolphin Surf），起售价为22990 欧元（约18.85万元人民币），续航322公里；高配版 24990欧元（约20.49万元人民币），续航507公里。本月的促销活动将起售价降至 19990 欧元（约16.39 万元人民币）。 比亚迪欧洲地区董事总经理玛丽亚·格拉齐亚·达维诺（Maria Grazia DaVino）在柏林的发布会上表示， 紧凑型细分市场是"欧洲电动化的下一个前沿阵地"，蕴藏着巨大潜力。 汽车研究机构Jato Dynamics高级分析师费利佩·穆尼奥斯（Felipe ...

| 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 首届全球心血管大会 | | --- | --- | | 即将召开： | | | 2025年6月12日，首届全球医美科技大会 | | | 2025年7月17日，第二届全球医疗科技大会 | | | 2025年9月4-5日，第三届全球手术机器人大会 | | 近日，美敦力（Medtronic, NYSE: MDT）宣布其 两大核心业务部门 ——心血管（Cardiovascular）与颅脑脊柱疗法（Cranial & Spinal Therapies, CST）的人事 调整： 服务公司超过20年的高管Sean Salmon将于2025年9月正式离任，其职位由Skip Kiil接任；同时，Michael Carter升任CST业务负责人 。 这场组织再造，远不止岗位更迭，更是一次聚焦核心、重塑路径、再启增长的系统信号。 # 人事集中调整：内部提拔，匹配落地执行周期 在本轮人事调整中，美敦力完成了对两位核心业务负责人的"平稳交接"： Sean Salmon 自2004年加入美敦力，曾长期负责心血管与糖尿病板块，是Micra无导线起搏器、TAVR系统等项目的重要 ...

Core Viewpoint - Medtronic is expected to report earnings on May 21, 2025, with consensus estimates indicating earnings per share of $1.58 and revenues of $8.82 billion, showing growth compared to the previous year's earnings of $1.46 per share and revenues of $8.59 billion [2][3] Financial Performance - Medtronic has a market capitalization of $110 billion and generated $33 billion in revenue over the last twelve months, with an operating profit of $6.0 billion and a net income of $4.3 billion [3] Historical Earnings Trends - Over the past five years, Medtronic's stock has shown a favorable one-day return following earnings announcements in 53% of instances, with a median return of 2.5% and a maximum of 4.6% [1][8] - In the last three years, the percentage of positive one-day returns has declined to 42%, with the median of positive returns at 2.5% and negative returns at -4.5% [8] Trading Strategies - Traders can utilize historical trends to position themselves before and after earnings announcements, assessing the likelihood of positive or negative responses [7] - A strategy involves analyzing the correlation between short-term and medium-term returns post-earnings to inform trading decisions [5][6]

Core Insights - Medtronic plc is expanding its global presence in the Cardiovascular business, which is expected to support growth in upcoming quarters [1] - The company is gaining market share in Neuroscience, particularly in Cranial and Spinal technologies, aided by strong growth and competitor exits [1] - International expansion remains robust, contributing significantly to revenue growth [1] Cardiovascular Business - Medtronic's cardiac rhythm management segment continues to lead the market, driven by strong performance in Defibrillation Solutions and cardiac pacing therapies [3] - The fiscal third quarter of 2025 saw the cardiovascular portfolio grow in the mid-single digits, with the Cardiac Ablation Solutions business achieving 22% growth [4] - The next-generation Micra AV2 and VR2 leadless pacemakers are key drivers of growth as they penetrate new and existing markets [3] Neuroscience Portfolio - The Neuroscience portfolio, particularly Cranial and Spinal technologies, is experiencing strong growth, with Medtronic gaining market share as competitors exit the market [5] - In Neuromodulation, the Inceptiv spinal cord stimulator drove 12% growth in the fiscal third quarter, while brain modulation saw 15% global growth and 26% growth in the U.S. [6] International Expansion - Nearly 49% of Medtronic's revenues were generated internationally in the third quarter of fiscal 2025, with emerging markets growing in high-single digits [7] - Significant growth was noted in India (high-teens), Eastern Europe (mid-teens), and low-double-digit growth in Southeast Asia, the Middle East, and Africa [9] Financial Performance - Medtronic has a market capitalization of $108.05 billion and an earnings yield of 6.92%, significantly higher than the industry's yield of 0.05% [2] - The Zacks Consensus Estimate for fiscal 2025 earnings per share (EPS) is $5.46, with revenues estimated at $33.48 billion, reflecting a 3.4% increase from the previous year [12]

Core Viewpoint - Medtronic is facing challenges in the fiscal fourth quarter of 2025 due to rising costs, geopolitical pressures, and declining earnings estimates despite previous earnings beats [3][4][6]. Financial Performance - Medtronic's adjusted earnings for the last reported quarter were $1.39, exceeding the Zacks Consensus Estimate by 2.21% [1] - The Zacks Consensus Estimate for fiscal fourth-quarter revenues is $8.81 billion, indicating a year-over-year growth of 2.6% [2] - The consensus estimate for fourth-quarter earnings is $1.58 per share, reflecting an 8.2% rise year-over-year [2] - Earnings estimates for the fourth quarter have declined by 1.9% over the past 90 days [2] Challenges and Headwinds - Rising costs and expenses due to inflation and geopolitical pressures are impacting profitability [3] - The tariff environment is affecting financial outlook, particularly due to Medtronic's manufacturing presence in Mexico and Canada [4] - Lower procedural volumes in elective surgeries and other medical procedures are putting pressure on the bottom line [6] - Unfavorable currency movements are expected to negatively impact revenues by $125 million to $175 million in the fourth quarter [8] Growth Opportunities - Despite challenges, Medtronic has shown resilience with mid-single-digit organic revenue growth [9] - Key growth areas include pulse field ablation, TAVR, neuromodulation, and diabetes businesses, driven by new product launches [10][12][13] - The company has made foundational changes to improve operations and is focusing on fast-growth MedTech markets [15][16] Market Position - Medtronic's stock has declined 5.9% in the fiscal fourth quarter, underperforming compared to industry peers [20] - The company's shares trade at a Price/Earnings ratio of 14.24X, below the industry average of 21.71X and the S&P 500's 20.43X [24][25] Conclusion - Medtronic has significant long-term growth potential but faces macroeconomic headwinds and rising expenses that could impact bottom-line growth [26]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月18日，美敦力公司（纽约证券交易所代码：MDT）公布了其2025财年第三季度（Q3）的财务业绩。 *美敦力以每年的4月27日为财年结束日，因此，2025财年第三季度于2025年1月24日结束。 #财报亮点 美敦力董事长兼首席执行官 Geoff Martha 表示："本季度我们实现了强劲的盈利，在 连续第九个季度 实现中个位数有机收入增长的推动下， 毛 利率和营业利润率均显著提升。 我们开始看到在突破性创新领域的长期投资成果，例如脉冲场消融技术，这些投资正在推动增长。" # 心血管业务 心血管业务组合包括 心脏节律与心力衰竭（CRHF）、结构性心脏病与主动脉（SHA）以及冠状动脉与外周血管（CPV）部门 。营收为 30.37亿 美元 ，按报告基准增长 3.7% ，按有机基准增长 5.0% 。 其中，CRHF和SHA部门实现中个位数增长，CPV部门实现低个位数增长。 CRHF： 心脏节律管理业务实现中个位数增长，主要得益于 心脏起搏治疗业务 的 ...

2025年1月7日， Integer Holdings Corporation 宣布以 1.52 亿美元（约合11亿人民币） 收购了 Precision Coating 的大部分资产。 # Integer Holdings Corporation的版图扩张之路 1. Pulse Technologies 收购日期：2024年1月10日 收购金额：1.4亿美元 公司背景：Pulse Technologies是一家总部位于宾夕法尼亚州的工程和代工制造公司，专注于医疗设备组件的复杂微加工。此次收购增强了Integer在高需求市 场中的开发和制造能力。 Integer Holdings Corporation （纽约证券交易所代码：ITGR）成立于 1970年，其总部位于德克萨斯州普莱诺。 该公司的品牌包括 Greatbatch Medical ® 和 Lake Region Medical ® 。 作为全球最大的医疗器械合同开发和制造组织 （CDMO） 之一，Integer Holdings Corporation专注于创新的高质量医疗设备技术，其产品广泛应用于 介入心 脏病学、神经调节、血管通路、整形外科 等多个 ...